Market Overview

UPDATE: Credit Suisse Initiates Sunesis Pharmaceuticals at Outperform Ahead of Phase II Data

Share:
Related SNSS
Sunesis Pharmaceuticals Announces Submission of a Marketing Authorization Application for Vosaroxin for the Treatment of Acute Myeloid Leukemia in Europe
Sunesis Pharmaceuticals Announces Presentation of Results Phase 1 Trial of Vosaroxin + Azacitidine at #ASH2015

Credit Suisse initiated coverage on Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) with an Outperform rating and a $7.00 price target.

Credit Suisse commented, "SNSS is a binary risk stock for which upside potential and probability of success are not fully reflected in the current share price. In part, we believe this is because the Phase III read out for vosaroxin is not expected until early 2014. However, we believe that shares could move significantly higher ahead of the event. Investors with binary risk tolerance should consider owning SNSS through the VALOR results. SNSS owns global rights to vosaroxin (owes a midteen royalty), so positive results would put SNSS on a path to commercial profitability or a potential premium acquisition."

Sunesis Pharmaceuticals closed at $4.00 on Monday.

Latest Ratings for SNSS

DateFirmActionFromTo
Jan 2016Cantor FitzgeraldUpgradesHoldSpeculative Buy
Jul 2015Cowen & CompanyDowngradesOutperformMarket Perform
Jun 2015Roth CapitalMaintainsBuy

View More Analyst Ratings for SNSS
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (SNSS)

View Comments and Join the Discussion!

Get Benzinga's Newsletters